ArticleCancer immunology research2019
A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
Article in Cancer immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.Nature medicine · 2024Trial
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses.International journal of molecular sciences · 2026Article
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nature cancer · 2026Article
- EPIC: multi-objective guided diffusion for epitope design in TCR-pMHC complexes.Bioinformatics (Oxford, England) · 2026Article
- Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.Journal for immunotherapy of cancer · 2026Article
- In silico design of the multi-epitope vaccine for lung adenocarcinoma based on hub gene-derived neoantigens.BMC cancer · 2026Article
- synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy.Cancer immunology, immunotherapy : CII · 2026Article
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
- Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccine.NPJ vaccines · 2025Article
- Article
- DNA Vaccines in the Post-mRNA Era: Engineering, Applications, and Emerging Innovations.International journal of molecular sciences · 2025Review
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.NPJ vaccines · 2025Article
- DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Personalized Immunity: Neoantigen-Based Vaccines Revolutionizing Hepatocellular Carcinoma Treatment.Cancers · 2025Review
- Advances in nucleic acid-based cancer vaccines.Journal of biomedical science · 2025Review
- Vaccine approaches to treat urothelial cancer.Human vaccines & immunotherapeutics · 2024Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
T-cell recognition of cancer neoantigens is important for effective immune-checkpoint blockade therapy, and an increasing interest exists in developing personalized tumor neoantigen vaccines. Previous studies utilizing RNA and long-peptide neoantigen vaccines in preclinical and early-phase clinical studies have shown immune responses predominantly driven by MHC class II CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.